Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:10:43 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CSLLY - CSL LTD SPON ADR EACH REPR 0.5 ORD - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSLLY - Qnot subscribed86.8225-0.0955-0.152.24,46840185.975  87.10  85.975105.11  71.5116:15:41Mar 1915 min RT 2¢

Recent Trades - Last 10 of 401
Time ETExPriceChangeVolume
16:15:41Q93.106.1828
16:11:06Q86.75-0.16830
15:59:59Q86.89-0.02819
15:59:39Q86.76-0.1585
15:58:09Q86.825-0.0931
15:57:07Q86.8225-0.0955159
15:51:49Q86.731-0.1876
15:49:25Q86.81-0.108268
15:49:19Q86.81-0.108107
15:49:19Q86.85-0.068100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-03-19 07:00U:CSLLYNews ReleaseFerinject(TM) approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
2024-03-06 09:00U:CSLLYNews ReleaseCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
2024-02-23 07:06U:CSLLYNews ReleaseTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
2024-02-12 22:54U:CSLLYNews ReleaseHalf year reported NPATA US$2 billion ‚ ¹, ‚ ² Up 13% at constant currency ‚ ³
2024-02-11 17:47U:CSLLYNews ReleaseCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
2024-02-05 08:30U:CSLLYNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2024-01-16 08:00U:CSLLYNews ReleaseHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
2024-01-03 08:00U:CSLLYNews ReleaseCSL Behring Announces Availability of Hizentra ‚ ® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics ¢ € ™ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-21 08:00U:CSLLYNews ReleaseCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-14 14:47U:CSLLYNews ReleaseCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
2023-12-11 19:30U:CSLLYNews ReleaseCSL Behring's HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
2023-11-28 08:05U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
2023-11-28 08:00U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ¢ € ™ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
2023-11-24 02:00U:CSLLYNews ReleaseIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment
2023-10-27 10:00U:CSLLYNews ReleaseCSL and uniQure Win 2023 Prix Galien USA Award
2023-10-26 14:14U:CSLLYNews ReleaseHealth Canada Authorizes CSL's HEMGENIX ® (etranacogene dezaparvovec) as First Gene Therapy for Hemophilia B